 ;templatestyles src="Chembox/styles.css"/ ;
Chemical compound
Bentiromide is a peptide used as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy. Bentiromide is not available in the United States or Canada; it was withdrawn in the US in October 1996.
Side effects.
Headache and gastrointestinal disturbances have been reported in patients taking bentiromide.
Mechanism of action.
Bentiromide is given by mouth as a noninvasive test. It is broken down by the pancreatic enzyme chymotrypsin, yielding p-aminobenzoic acid (PABA). The amount of PABA and its metabolites excreted in the urine is taken as a measure of the chymotrypsin-secreting activity of the pancreas.
Chemistry.
Synthesis.
It is synthesized by amide formation between ethyl "p"-aminobenzoate and "N"-benzoyl-tyrosine using "N"-methyl-morpholine and ethyl chlorocarbonate for activation. The resulting L-amide is selectively hydrolyzed by sequential use of dimsyl sodium (NaDMSO) and dilute acid to give bentiromide (4).
References.
 ;templatestyles src="Reflist/styles.css" / ;